SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-021255
Filing Date
2020-05-05
Accepted
2020-05-05 16:12:32
Documents
91
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akba-10q_20200331.htm   iXBRL 10-Q 3457386
2 EX-10.1 akba-ex101_298.htm EX-10.1 417795
3 EX-31.1 akba-ex311_8.htm EX-31.1 17684
4 EX-31.2 akba-ex312_7.htm EX-31.2 17682
5 EX-32.1 akba-ex321_9.htm EX-32.1 12265
  Complete submission text file 0001564590-20-021255.txt   14248694

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA akba-20200331.xsd EX-101.SCH 97485
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE akba-20200331_cal.xml EX-101.CAL 88908
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE akba-20200331_def.xml EX-101.DEF 335021
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20200331_lab.xml EX-101.LAB 645900
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20200331_pre.xml EX-101.PRE 528089
74 EXTRACTED XBRL INSTANCE DOCUMENT akba-10q_20200331_htm.xml XML 2935804
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 20848959
SIC: 2834 Pharmaceutical Preparations